Latest Headlines

  1. Asimov Launches RNA Edge, A Lab-In-The-Loop Platform For AI Optimization Of RNA Therapeutic Candidates 3/19/2026

    Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, announces the launch of its RNA Edge System, an integrated AI, synthetic biology, and laboratory platform to optimize RNA therapies.

  2. Abzena Recognized As A Market-Leading Antibody-Drug Conjugate CDMO In Frost & Sullivan Radar Report 3/18/2026

    Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, today announced it has been named a leader in the Frost Radar™ Report for Antibody Drug Conjugate Contract Development and Manufacturing Organizations.

  3. Primrose Bio's Prima RNApols™ ExTend Named Among The Top RNA Polymerases For mRNA Synthesis In Independent University Of British Columbia Study 3/17/2026

    In an independent RNA polymerase comparison conducted by UBC, Prima RNApols™ ExTend, enzyme number 13 in the study, was named among the top performers for mRNA synthesis based on a balanced profile of competitive IVT yield and integrity with best-in-set dsRNA minimization.

  4. CEO Insights And Trends: The Future Of The Sterile Filling CDMO Industry 3/17/2026

    Denis Johnson, CEO, explores developments in the CDMO sector and reveals how GRAM is gearing up for its latest phase of growth in sterile filling.

  5. BD Announces $110 Million To Support U.S. Pharmaceutical Supply Chain For Biologic Drugs 3/16/2026

    BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a $110 million investment to expand its production of prefillable syringes, helping accelerate biologic and GLP-1 drug delivery and supporting pharmaceutical reshoring in the U.S.

  6. BD And Ypsomed Expand Partnership To Address Rapidly Growing Biologics Market 3/16/2026

    BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Ypsomed, a leading developer of injection systems, are strengthening their collaboration with the development of a 5.5 mL version of the BD Neopak™ XtraFlow™ Glass Prefillable Syringe.

  7. Emerson Streamlines Life Sciences Recipe Creation For Faster Time To Market 3/9/2026
  8. LOTTE BIOLOGICS Signs Letter Of Intent (LOI) For Strategic Collaboration With U.S.-Based Multinational Company That Has Also Presence And Operation In Japan And Taiwan 3/6/2026

    LOTTE BIOLOGICS (CEO James Park) announced that it has signed a Letter of Intent (LOI) for strategic business collaboration with a multinational biotechnology company headquartered in the United States. 

  9. LOTTE BIOLOGICS Signs Strategic Partnership Agreement With U.S.-Based Asimov 3/6/2026

    LOTTE BIOLOGICS (CEO James Park) on March 13th that it has signed a Memorandum of Understanding (MOU) with Asimov, a company headquartered in Boston, Massachusetts, to collaborate in the Contract Development and Manufacturing Organization (CDMO) business.

  10. Minaris Launches AgentSCREEN Adventitious Virus Detection By NGS To Simplify Viral Safety Testing For Cell Banks And Cell-Based Samples 3/4/2026

    Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider, today announced the launch of AgentSCREEN Adventitious Virus Detection by Next Generation Sequencing (NGS).